Dr. Ledermann on Phase III ARIEL3 Results in Ovarian Cancer

Jonathan Ledermann, MD
Published: Saturday, Sep 09, 2017



Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the phase III results of the ARIEL3 trial in ovarian cancer during the 2017 ESMO Congress.

This trial included patients with ovarian cancer who did and do not harbor a BRCA mutation, Ledermann explains. The design of the trial was to explore the investigator-assessed progression-free survival (PFS) with maintenance rucaparib (Rubraca) first in patients with BRCA mutations, then in patients who had homologous recombination deficiency-defined disease as an increase in loss of heterozygosity (LOSS) through a Foundation Medicine assay, and then the intention-to-treat population, which was all-comers.

Results showed that rucaparib led to a significant improvement in PFS across all groups. The biggest activity was observed in patients with BRCA mutations, but there was also significant benefit seen in those who were LOH positive. Moreover, there were also improvements in PFS in LOH-negative, BRCA wild-type patients with maintenance rucaparib, he adds.

<<< View more from the 2017 ESMO Congress


Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the phase III results of the ARIEL3 trial in ovarian cancer during the 2017 ESMO Congress.

This trial included patients with ovarian cancer who did and do not harbor a BRCA mutation, Ledermann explains. The design of the trial was to explore the investigator-assessed progression-free survival (PFS) with maintenance rucaparib (Rubraca) first in patients with BRCA mutations, then in patients who had homologous recombination deficiency-defined disease as an increase in loss of heterozygosity (LOSS) through a Foundation Medicine assay, and then the intention-to-treat population, which was all-comers.

Results showed that rucaparib led to a significant improvement in PFS across all groups. The biggest activity was observed in patients with BRCA mutations, but there was also significant benefit seen in those who were LOH positive. Moreover, there were also improvements in PFS in LOH-negative, BRCA wild-type patients with maintenance rucaparib, he adds.

<<< View more from the 2017 ESMO Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x